BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $85 from $81 and keeps a Buy rating on the shares. The company’s SLK is well-positioned to deliver best in class/disease efficacy in upcoming 16-week Phase 3 VELA data expected around September 2025, the analyst tells investors in a research note. Enrollment has completed in both VELA trials in 12 months, representing the fastest enrollment timeline for any Phase 3 program in hidradenitis suppurativa by a wide margin, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating
- MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating
- MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating
- MoonLake Immunotherapeutics Hosts Capital Markets Day
- MoonLake Immunotherapeutics Secures $500M Financing for Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue